Drs Alicia Morgans and Charles Ryan review advancements in the treatment in prostate cancer from 2020. Dr. Ryan first reviews the Phase 3 HERO study, Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer (ClinicalTrials.gov Identifier: NCT03085095), comparing relugolix, an oral gonadotropin-releasing hormone antagonist, to leuprolide in a 2:1 randomization which led to a…
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and…
Alicia Morgans engages in a discussion with Benjamin Lowentritt, focusing on comprehensive care for prostate cancer patients, particularly those with de novo metastatic hormone-sensitive disease.…
Gerhardt Attard discusses advancing the treatment of advanced hormone-sensitive prostate cancer through biological research. Dr. Attard’s work focuses on two main areas: analyzing tumor samples…
At the 2024 UCSF-UCLA PSMA Conference, Michael Morris reviews the VISION and TheraP trials, underscoring their significance in advancing PSMA PET imaging and radioligand therapy…
Non Muscle Invasive Bladder Cancer (NMIBC), Sequential Gemcitabine and Docetaxel, Bacillus Calmette-Guérin (BCG), Gem/Doce. global BCG supply shortage, radical cystectomy, efficacy of sequential Gem/Doce treatment…
Zach Klaassen and Gautam (Tom) Jayram explore the use of blue light cystoscopy in bladder cancer. Dr. Jayram explains its mechanism, where an optical agent,…
Sam Chang engages with Josh Meeks to discuss nadofaragene firadenovec’s role in treating BCG-unresponsive bladder cancer. They consider the significance of clinical trials and FDA…
Michael Morris highlights notable prostate cancer trials, focusing on AMG 509, a bispecific antibody targeting STEAP1 and CD3. This promising early-phase study, still determining optimal…
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), androgen deprivation therapy (ADT), apalutamide, enzalutamide, Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer,…
Asmaa El-Kenawi discusses her group’s research on therapeutic resistance in cancer, particularly focusing on the role of methionine in driving resistance. Published in “Cancer Research,”…
